Abstract: 1-R-4-(omega-substituted alkyl)-3,3-diphenyl-2-pyrrolidinones of the formula ##STR1## wherein R is hydrogen, lower alkyl, cyclohexyl or benzyl, R.sup.1 is hydrogen, chloro, bromo, fluoro, trifluoromethyl or lower alkoxy, R.sup.2 is hydrogen, chloro, bromo, or fluoro, A is hydroxy, lower-alkylcarbonyloxy or lower-alkoxycarbonyl and n is 1, 2 or 3 having analgetic and antidiarrheal activity are disclosed. The pharmaceutically acceptable acid addition salts of the bases are within the scope of the present invention.

Abstract: Novel alkenyl- and alkanylamines having the formula: ##STR1## wherein Am is lower-alkylamino, di-lower-alkylamino and piperidino; A is methylene and methylidyne; R is hydrogen, lower-alkyl, lower-alkoxy, halogen and trifluoromethyl; m is zero and one; n is one and two; X is halogen and the pharmaceutically acceptable acid addition salts thereof. The alkenylamines are prepared by contacting 1-cyclopropyl-1-phenyl-.omega.-amino-1-alkanols with strong mineral acids. The alkanylamines are prepared by hydrogenation of the alkenylamines. Some of the compounds exhibit potent antagonism to the depressant effects of tetrabenazine.

Abstract: Novel pharmaceutical methods, combinations and compositions for reducing gastric bleeding during aspirin therapy for inflammation are disclosed. Compounds used in combination with aspirin are phenylalkylamines and phenylalkylureas having the formula: ##STR1## wherein Z is selected from the group consisting of --NHR.sup.2 or ##STR2## and R is selected from the group consisting of hydrogen, halogen, lower-alkoxy and trifluoromethyl and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are selected from the group consisting of hydrogen and lower-alkyl, where R.sup.3 and R.sup.4 taken together with the adjacent nitrogen atom may form a heterocyclic ring selected from the group of piperidino, pyrrolidino, piperazino, and morpholino.

Abstract: 1-R-3-Pyrrolidinyl-.alpha.,.alpha.-diphenylacetamides, -acetonitriles and -methanes represented by the following formula: ##STR1## wherein R represents hydrogen, lower alkyl, lower cycloalkyl or phenyllower alkyl, R.sup.1 represents hydrogen or lower alkyl, and Y is carbamoyl, di-lower-alkylcarbamoyl, pyrrolidinocarbonyl, morpholinocarbonyl, cyano or hydrogen having antiarrhythmic activity are disclosed. Pharmaceutically acceptable acid addition salts are included as part of the invention.

Abstract: Novel 1-cyclopropyl-1-phenyl-.omega.-amino-1-alkanols and 1-lower-alkylacyl derivatives are described having the formula: ##STR1## wherein; Am is lower-alkylamino, di-lower-alkylamino and piperidino, R is hydrogen and lower alkanoyl, R.sup.1 is hydrogen, halogen, lower-alkoxy, lower-alkyl and trifluoromethyl, and n is two and three. The compounds wherein R is hydrogen have antidepressant properties and those wherein R is lower-alkanoyl have analgetic properties.

Abstract: 1-R-3-Pyrrolidinyl-.alpha.-phenyl-.alpha.-(2-pyridyl)acetamides, -acetonitriles and -methanes represented by the following formula: ##SPC1##Wherein R represents lower alkyl, lower cycloalkyl or phenyllower alkyl and Y is carbamoyl, cyano or hydrogen having antiarrhythmic activity are disclosed. Pharmaceutically acceptable acid addition salts are included as part of the invention.

Abstract: Novel 1-cyclopropyl-1-phenyl-.omega.-amino-1-alkanols are described having the formula: ##SPC1##Wherein;Am is lower-alkylamino and di-lower-alkylamino and piperidino, R is hydrogen, halogen, lower-alkoxy, lower-alkyl and trifluoromethyl, and n is 2 and 3. The compounds have antidepressant properties.

Abstract: Novel alkenyl- and alkanylamines having the formula: ##EQU1## WHEREIN Am is lower-alkylamino, di-lower-alkylamino and piperidino; A is methylene and methylidyne; R is hydrogen, lower-alkyl, lower-alkoxy, halogen and trifluoromethyl; m is zero and one; n is one and two; X is halogen and the pharmaceutically acceptable acid addition salts thereof. The alkenylamines are prepared by contacting 1-cyclopropyl-1-phenyl-.omega.-amino-1-alkanols with strong mineral acids. The alkanylamines are prepared by hydrogenation of the alkenylamines. Some of the compounds exhibit potent antagonism to the depressant effects of tetrabenazine.

Abstract: Novel 4-(5- and 7-)benzoylindolin-2-ones of the formula: ##SPC1##Wherein R is hydrogen, lower-alkyl, or methylthio, R.sup.1 is hydrogen or lower-alkyl, R.sup.2 is lower-alkyl, lower-alkoxy, halogen, nitro or trifluoromethyl, R.sup.3 is hydrogen, halogen or lower-alkoxy, and n is 0, 1 or 2, are prepared by (a) acylation of indolin-2-one to give 5-benzoylindoline-2-one, (b) cyclization of 2-acetamido-3-benzoylphenylacetic acid or ethyl 2-acetamido-3-benzoylphenylacetate to give 7-benzoyindoline-2-one, or (c) by reacting aminobenzophenones with alkyl .alpha.(methylthio)acetates to give alkyl 2-amino-3-(5- or 6-)benzoyl-.alpha.-(methylthio)phenylacetates which are cyclized and demethylthiolated to 4-(5- and 7-)benzoylindolin-2-ones. The novel compounds possess anti-inflammatory activity and are intermediates for the preparation of 2-amino-3-(5- or 6-) benzoylphenylacetic acids which posess anti-inflammatory properties.

Abstract: The preparation of compounds of the formula ##SPC1##Wherein R is selected from the group consisting of hydrogen and chlorine is described. The compounds are useful as chemical intermediates and as anti-inflammatory agents.